1h Free Analyst Time
The plasma fractionation market is forecasted to grow by USD 15.68 billion during 2024-2029, accelerating at a CAGR of 7.3% during the forecast period. The report on the plasma fractionation market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.Speak directly to the analyst to clarify any post sales queries you may have.
The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by growing prevalence of plasma products treated in respiratory diseases and aatd, growing list of plasma-derived products, and increasing in mergers and acquisitions producing plasma-based products.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market size data, segment with regional analysis and vendor landscape in addition to an analysis of the key companies. Reports have historic and forecast data.
The plasma fractionation market is segmented as below:
By Product
- Immunoglobulins
- Albumin
- Coagulation factor concentrates
- Protease inhibitors
- Others
By Application
- Immunology
- Neurology
- Hematology
- Critical care
- Others
By Technology
- Chromatography
- Filtration
- Precipitation
By Geographical Landscape
- North America
- Europe
- Asia
- Rest of World (ROW)
The report on the plasma fractionation market covers the following areas:
- Plasma Fractionation Market sizing
- Plasma Fractionation Market forecast
- Plasma Fractionation Market industry analysis
The report presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive primary and secondary research. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast accurate market growth.
Table of Contents
1 Executive Summary
2 Market Analysis
3 Market Landscape
4 Market Sizing
5 Historic Market Size
6 Qualitative Analysis
7 Five Forces Analysis
8 Market Segmentation by Product
9 Market Segmentation by Application
10 Market Segmentation by Technology
11 Customer Landscape
12 Geographic Landscape
13 Drivers, Challenges, and Opportunity/Restraints
14 Competitive Landscape
15 Competitive Analysis
16 Appendix
List of Exhibits
Executive Summary
The following companies are recognized as the key players in the global plasma fractionation market: ADMA Biologics Inc., Bharat Serums and Vaccines Ltd., CSL Ltd., Emergent BioSolutions Inc., GC Biopharma Corp., Grifols SA, Intas Pharmaceuticals Ltd., Kamada Ltd., Kedrion SpA, LFB SA, Merck KGaA, Octapharma AG, PlasmaGen BioSciences Pvt. Ltd., Prothya Biosolutions Netherlands BV, Sanquin, SK Inc., Takeda Pharmaceutical Co. Ltd., and Virchow Laboratories Ltd..Commenting on the report, an analyst from the research team said: "The latest trend gaining momentum in the market is growing elderly population and related disorders."
According to the report, one of the major drivers for this market is the growing prevalence of plasma products treated in respiratory diseases and aatd.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- ADMA Biologics Inc.
- Bharat Serums and Vaccines Ltd.
- CSL Ltd.
- Emergent BioSolutions Inc.
- GC Biopharma Corp.
- Grifols SA
- Intas Pharmaceuticals Ltd.
- Kamada Ltd.
- Kedrion SpA
- LFB SA
- Merck KGaA
- Octapharma AG
- PlasmaGen BioSciences Pvt. Ltd.
- Prothya Biosolutions Netherlands BV
- Sanquin
- SK Inc.
- Takeda Pharmaceutical Co. Ltd.
- Virchow Laboratories Ltd.
